Comparative Effectiveness and Safety of Upadacitinib and Vedolizumab in Biologic-Experienced Patients With Ulcerative Colitis: A Retrospective Study
{{output}}
Objectives: Upadacitinib (UPA) and vedolizumab (VDZ) have been approved to treat moderate-to-severe ulcerative colitis (UC); however, direct comparative data between these two regimens are lacking. We aimed to compare the effecti... ...
